Skip to content Skip to footer
Viewpoints_Dr. Andrew Krivoshik

PharmaShots Interview: Astellas’ Dr. Andrew Krivoshik Shares Insights on P-II FAST Study of Zolbetuximab

In an interview with PharmaShots, Dr. Andrew Krivoshik, Senior Vice President and Oncology Therapeutic Area Head at Astellas, shared his views on the P-II FAST study result published in the journal Gastric Cancer and highlights the data published in Annals of Oncology.Shots:The data from P-II FAST study evaluating zolbetuximab + EOX in 1L patients with advanced gastric and…

Read more